UB Paderborn / Katalog / Suche / in CDI

Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)

Annals of oncology, 2016-12, Vol.27 (12), p.2236-2241

2016

Volltextzugriff (PDF)

000197 THE ANTI-IDIOTYPIC MONOCLONAL ANTIBODY ACA125 IN PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PERITONEAL CANCER. A PHASE II TRIAL OF THE AGO-OVAR

International journal of gynecological cancer, 2005-09, Vol.15 (Suppl 2), p.106-106

2005

Volltextzugriff (PDF)

NEUROPROTECTION WITH AMIFOSTINE IN THE 1ST-LINE TREATMENT OF ADVANCED OVARIAN CANCER WITH CARBOPLATIN/TAXANE-BASED CHEMOTHERAPY – A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE II-STUDY FROM THE AGO OVARIAN CANCER STUDY GROUP

International journal of gynecological cancer, 2004-09, Vol.14 (Suppl 1), p.101-101

2004

Volltextzugriff (PDF)

Abstract P1-13-01: Final results of the ASG1-3 study, a randomized phase III study comparing a standard dose chemotherapy with epirubicin/cyclophosphamide and paclitaxel with a dose dense regimen with epirubicin and paclitaxel

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P1-P1-13-01

2019

Volltextzugriff (PDF)

Abstract P1-14-05: Phase I/II Trial of primary chemotherapy with non-pegylated liposomal doxorubicin, paclitaxel and lapatinib in patients with HER2-positive, early stage breast cancer

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P1-P1-14-05

2012

Volltextzugriff (PDF)

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

The New England journal of medicine, 2011-12, Vol.365 (26), p.2484-2496

2011

Volltextzugriff (PDF)

AGO-OVAR 14: A retrospective study evaluating the reasons for non-participating in trials in patients with ovarian cancer (OC) treated in coordinating centers of the AGO Ovarian Cancer Study Group

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.5081-5081

2004

Volltextzugriff (PDF)

AGO-OVAR 14: A retrospective study evaluating the reasons for non-participating in trials in patients with ovarian cancer (OC) treated in coordinating centers of the AGO Ovarian Cancer Study Group

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.5081-5081

2004

Volltextzugriff (PDF)

Greening the Operating Room: Results of a Scalable Initiative to Reduce Waste and Recover Supply Costs

Neurosurgery, 2019-09, Vol.85 (3), p.432-437

2019

Volltextzugriff (PDF)

Population-based study of the incidence of sudden unexplained death in epilepsy

Neurology, 1998-11, Vol.51 (5), p.1270-1274

1998

Volltextzugriff (PDF)

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

The New England journal of medicine, 2019-02, Vol.380 (7), p.617-628

2019

Volltextzugriff (PDF)

Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer

Annals of oncology, 2013-09, Vol.24 (9), p.2316-2324

2013

Volltextzugriff (PDF)

Use of PASEF for Accelerated Protein Sequence Confirmation and De Novo Sequencing with High Data Quality

Methods in molecular biology (Clifton, N.J.), 2022, Vol.2313, p.207

2022

Volltextzugriff (PDF)

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

Annals of oncology, 2014-12, Vol.25 (12), p.2363-2372

2014

Volltextzugriff (PDF)

A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer

Annals of oncology, 2013-04, Vol.24 (4), p.937-943

2013

Volltextzugriff (PDF)

176O Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)

Annals of oncology, 2022-11, Vol.33, p.S1503-S1504

2022

Volltextzugriff (PDF)

A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study

Annals of oncology, 2012-09, Vol.23 (9), p.2259-2264

2012

Volltextzugriff (PDF)

Thermal Vaporization of Biological Nanoparticles: Fragment-Free Vacuum Ultraviolet Photoionization Mass Spectra of Tryptophan, Phenylalanine−Glycine−Glycine, and β-Carotene

The journal of physical chemistry. A, Molecules, spectroscopy, kinetics, environment, & general theory, 2006-02, Vol.110 (6), p.2106-2113

2006

Volltextzugriff (PDF)

Vorhersage des Tumorrestes beim fortgeschrittenen Ovarialkarzinom durch Nutzung einer Gesamt-Transkription-Expressionsanalyse. Eine Analyse der AGO-OVAR 11 (ICON7) Studie

Geburtshilfe und Frauenheilkunde, 2018, Vol.78 (10)

2018

Volltextzugriff (PDF)

Carboplatin/Caelyx/Bevacizumab vs. Carboplatin/Gemcitabine/Bevacizumab beim platinsensiblen Ovarialkarzinomrezidiv: Ergebnisse der prospektiv-randomisierten Phase III AGO-OVAR 2.21 Studie

Geburtshilfe und Frauenheilkunde, 2019, Vol.79 (8)

2019

Volltextzugriff (PDF)

782 Survival in advanced-stage ovarian carcinoma with high VEGF-A expression after addition of bevacizumab. Results from the German ICON7 patient cohort

International journal of gynecological cancer, 2021-10, Vol.31 (Suppl 3), p.A274-A274

2021

Volltextzugriff (PDF)

LION-PAW – Lymphonodectomy (LNE) in Ovarian Neoplasm – Pleasure Ability of Women Prospektive Substudie der multizentrischen AGO LION Studie

Geburtshilfe und Frauenheilkunde, 2018, Vol.78 (10)

2018

Volltextzugriff (PDF)

The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR

Annals of oncology, 2006-10, Vol.17 (10), p.1568-1577

2006

Volltextzugriff (PDF)

AGO-OVAR 12: Eine randomisierte, Placebo-kontrollierte Phase III-Studie zum Einsatz von Carboplatin und Paclitaxel ± Nintedanib beim fortgeschrittenen Ovarialkarzinom (GCIG/ENGOT-Intergroup-Studie)

Geburtshilfe und Frauenheilkunde, 2014, Vol.74 (S 01)

2014

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

000197 THE ANTI-IDIOTYPIC MONOCLONAL ANTIBODY ACA125 IN PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PERITONEAL CANCER. A PHASE II TRIAL OF THE AGO-OVAR

NEUROPROTECTION WITH AMIFOSTINE IN THE 1ST-LINE TREATMENT OF ADVANCED OVARIAN CANCER WITH CARBOPLATIN/TAXANE-BASED CHEMOTHERAPY – A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE II-STUDY FROM THE AGO OVARIAN CANCER STUDY GROUP

Abstract P1-13-01: Final results of the ASG1-3 study, a randomized phase III study comparing a standard dose chemotherapy with epirubicin/cyclophosphamide and paclitaxel with a dose dense regimen with epirubicin and paclitaxel

Abstract P1-14-05: Phase I/II Trial of primary chemotherapy with non-pegylated liposomal doxorubicin, paclitaxel and lapatinib in patients with HER2-positive, early stage breast cancer

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

AGO-OVAR 14: A retrospective study evaluating the reasons for non-participating in trials in patients with ovarian cancer (OC) treated in coordinating centers of the AGO Ovarian Cancer Study Group

AGO-OVAR 14: A retrospective study evaluating the reasons for non-participating in trials in patients with ovarian cancer (OC) treated in coordinating centers of the AGO Ovarian Cancer Study Group

Greening the Operating Room: Results of a Scalable Initiative to Reduce Waste and Recover Supply Costs

Population-based study of the incidence of sudden unexplained death in epilepsy

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial

Use of PASEF for Accelerated Protein Sequence Confirmation and De Novo Sequencing with High Data Quality

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer

176O Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)

A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study

Thermal Vaporization of Biological Nanoparticles: Fragment-Free Vacuum Ultraviolet Photoionization Mass Spectra of Tryptophan, Phenylalanine−Glycine−Glycine, and β-Carotene

Vorhersage des Tumorrestes beim fortgeschrittenen Ovarialkarzinom durch Nutzung einer Gesamt-Transkription-Expressionsanalyse. Eine Analyse der AGO-OVAR 11 (ICON7) Studie

Carboplatin/Caelyx/Bevacizumab vs. Carboplatin/Gemcitabine/Bevacizumab beim platinsensiblen Ovarialkarzinomrezidiv: Ergebnisse der prospektiv-randomisierten Phase III AGO-OVAR 2.21 Studie

782 Survival in advanced-stage ovarian carcinoma with high VEGF-A expression after addition of bevacizumab. Results from the German ICON7 patient cohort

LION-PAW – Lymphonodectomy (LNE) in Ovarian Neoplasm – Pleasure Ability of Women Prospektive Substudie der multizentrischen AGO LION Studie

The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR

AGO-OVAR 12: Eine randomisierte, Placebo-kontrollierte Phase III-Studie zum Einsatz von Carboplatin und Paclitaxel ± Nintedanib beim fortgeschrittenen Ovarialkarzinom (GCIG/ENGOT-Intergroup-Studie)

Suchergebnisse filtern